A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

The following contains links to social media websites including Bluesky, X, TikTok, Instagram, Facebook, and LinkedIn. "Make ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

A small percentage have had vision problems, but a direct causal link with the drugs has not been established.

Obesity is an epidemic in the United States, but more people are shedding pounds with the help of weight loss drugs.

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...